TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:
CGEN) today announced that the Company will host a conference call
at 10:00 AM ET on Tuesday, May 5, 2015 to review the first quarter 2015
results. The quarterly results will be released on the Company’s website
(www.cgen.com)
prior to the conference call.
To access the conference call, please dial 1-888-668-9141 from the US,
or +972-3-918-0609 internationally. The call will also be available via
live webcast through Compugen’s website, located at the following link.
A replay of the conference call will be available approximately two
hours after the completion of the live conference call. To access the
replay, please dial 1-888-295-2634 from the US or +972-3-925-5925
internationally. The replay will be available through May 7, 2015.
About Compugen
Compugen is a leading predictive drug discovery company focused on
monoclonal antibodies and therapeutic proteins to address important
unmet needs in the fields of oncology and immunology. The Company
utilizes a broad and continuously growing integrated infrastructure of
proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational biology
capabilities for the in silico (by computer) prediction and
selection of novel drug target candidates, which are then advanced in
its Pipeline Program. The discovery and development of monoclonal
antibody therapeutic candidates against selected Compugen-discovered
novel target candidates is performed by Compugen’s wholly-owned US
subsidiary located in South San Francisco. The Company's business model
includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery agreements,
in both cases providing Compugen with potential milestone payments and
royalties on product sales or other forms of revenue sharing. For
additional information, please visit Compugen's corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of terminology such as “will,”
“may,” “expects,” “anticipates,” “believes,” and “intends,” and describe
opinions about future events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements expressed
or implied by such forward-looking statements. Some of these risks
include: that Compugen’s business model is substantially dependent on
entering into collaboration agreements with third parties and may not be
successful in generating revenues, and that the development and
commercialization of therapeutic products includes many inherent risks,
including failure to receive regulatory approval. These and other
factors are more fully discussed in the "Risk Factors" section of
Compugen’s most recent Annual Report on Form 20-F as filed with the
Securities and Exchange Commission as well as other documents that may
be subsequently filed by Compugen from time to time with the Securities
and Exchange Commission. In addition, any forward-looking statements
represent Compugen’s views only as of the date of this release and
should not be relied upon as representing its views as of any subsequent
date. Compugen does not assume any obligation to update any
forward-looking statements unless required by law.